Clinical Research Directory

Inclusion Criteria: 1. 18 to 75 years of age at the time of informed consent. 2. Of African descent. 3. Biopsy-proven central centrifugal cicatricial alopecia with no other cause of hair loss. 4. Agrees to use no other medication to treat central centrifugal cicatricial alopecia for the duration of the study. 5. Women of childbearing potential must use highly effective contraception during the intervention period and for 28 days after the last dose, and must have negative pregnancy tests at screening and at baseline. 6. In otherwise good general health by medical history, physical examination and laboratory testing. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Any other form of alopecia, or any concomitant scalp or skin condition that would interfere with evaluation of study medication. 3. Active systemic disease that may cause hair loss. 4. Intralesional corticosteroids, oral JAK inhibitors, or any other treatment for central centrifugal cicatricial alopecia within 4 weeks of baseline. 5. Systemic immunosuppressive therapy within 8 weeks of baseline, or other non-biologic systemic agents within 4 weeks of baseline. 6. Participation in another interventional study within 4 weeks, or previous treatment with baricitinib. 7. Active tuberculosis, inadequately treated latent tuberculosis, hepatitis B, hepatitis C, or HIV infection. 8. Current or recent serious infection, or a history of recurrent eczema herpeticum. 9. Screening laboratory values outside protocol-specified hematologic, hepatic or renal limits. 10. Renal impairment. 11. History of venous thromboembolism or high risk for venous thromboembolism. 12. Myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Class III or IV heart failure within 12 weeks of screening. 13. History of lymphoproliferative disease, active malignancy, or malignancy in remission for less than 5 years. 14. Hypersensitivity to any component of study drug. 15. Live vaccine within 12 weeks of baseline or anticipated during the study. 16. Unable or unwilling to comply with study procedures for the duration of the study. 17. Investigator site personnel directly affiliated with this study, or their immediate family.